ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY - AN OVERVIEW

In Segment A, participants will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Harmless dosing routine. Further members might be enrolled with the determined monotherapy dosign regimen. In Phase B, individuals will acquire oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Segment C, membe